Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials - PubMed
6 hours ago
- #IL-23 inhibitor
- #psoriasis
- #meta-analysis
- Oral icotrokinra (JNJ-77242113) is a first-in-class oral peptide targeting the IL-23 receptor for moderate-to-severe plaque psoriasis.
- A meta-analysis of 5 RCTs (1,951 participants) showed significant efficacy in achieving IGA 0/1 (RR = 7.27) and PASI 75 (RR = 6.70) at week 16 vs. placebo.
- Higher skin clearance rates were observed (PASI 90 RR = 13.82; PASI 100 RR = 31.65), along with benefits in scalp-specific disease and patient-reported outcomes.
- Safety profile of icotrokinra was comparable to placebo, with no significant difference in adverse event rates.
- Trial sequential analysis (TSA) indicated insufficient evidence for definitive conclusions, highlighting the need for larger, long-term RCTs.